Pathophysiology and management of hepatic encephalopathy 2014 update: Ammonia toxicity and hyponatremia

Hyperammonemia is a major factor involved in the pathogenesis of hepatic encephalopathy (HE). Ammonia elicits astrocyte swelling and causes brain edema. In addition, hyponatremia, a condition frequently observed in hepatic cirrhosis, also exacerbates brain edema, potentially becoming a factor that e...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Hepatology research 2015-12, Vol.45 (12), p.1155-1162
Hauptverfasser: Iwasa, Motoh, Takei, Yoshiyuki
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1162
container_issue 12
container_start_page 1155
container_title Hepatology research
container_volume 45
creator Iwasa, Motoh
Takei, Yoshiyuki
description Hyperammonemia is a major factor involved in the pathogenesis of hepatic encephalopathy (HE). Ammonia elicits astrocyte swelling and causes brain edema. In addition, hyponatremia, a condition frequently observed in hepatic cirrhosis, also exacerbates brain edema, potentially becoming a factor that exacerbates HE. Therefore, as a treatment strategy for HE, alleviating ammonia toxicity is essential. In addition to restricting protein intake, synthetic disaccharides such as lactulose and lactitol, probiotics that improve gut flora, and rifaximin, an antibiotic with poor bioavailability, are also administrated. Additionally, branched‐chain amino acids and carnitine have also been administrated. Moreover, we investigated the current trend in the concomitant use of drugs with different mechanisms of action. In Japan, the V2 receptor antagonist tolvaptan can be administrated to hepatic cirrhosis patients with fluid retention. This drug is also useful as a countermeasure for hyponatremia in hepatic cirrhosis, and elucidating its effects in HE patients may therefore become an agenda in the future. These observations indicate that ammonia toxicity, gut flora control and low sodium control are major focuses in HE improvement and long‐term prognosis.
doi_str_mv 10.1111/hepr.12495
format Article
fullrecord <record><control><sourceid>wiley_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1111_hepr_12495</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>HEPR12495</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5275-a386a94bf251a7af66d6f73f2062a730cacf50e15a40e52b3fa3ebfa7553d2da3</originalsourceid><addsrcrecordid>eNp9kE1PwkAQhjdGI4he_AFmzybF_ejugjdCEEwIEoPReNkM7S5dpd2mLZH-e4sVj85lZpJnnkxehK4p6dOm7hKTF33KwqE4QV06UCwgPHw7bWY-kIHkoeygi7L8IIQqwsJz1GFCklAo2kWbJVSJz5O6dH7rNzWGLMYpZLAxqckq7C1u9FC5CJssMnkCW9-sSY0ZoSHe5TFU5h6P0tRnDnDl9y5yVatJ6txnUBUmdXCJzixsS3P123vo5WGyGs-C-dP0cTyaB5FgSgTQfAzDcG2ZoKDAShlLq7hlRDJQnEQQWUEMFRASI9iaW-BmbUEJwWMWA--h29YbFb4sC2N1XrgUilpTog9p6UNa-ietBr5p4Xy3Tk38hx7jaQDaAl9ua-p_VHo2WT4fpUF748rK7P9uoPjUUnEl9Otiqpd0uSJq8a7n_BtA3oZi</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Pathophysiology and management of hepatic encephalopathy 2014 update: Ammonia toxicity and hyponatremia</title><source>Wiley Online Library - AutoHoldings Journals</source><creator>Iwasa, Motoh ; Takei, Yoshiyuki</creator><creatorcontrib>Iwasa, Motoh ; Takei, Yoshiyuki</creatorcontrib><description>Hyperammonemia is a major factor involved in the pathogenesis of hepatic encephalopathy (HE). Ammonia elicits astrocyte swelling and causes brain edema. In addition, hyponatremia, a condition frequently observed in hepatic cirrhosis, also exacerbates brain edema, potentially becoming a factor that exacerbates HE. Therefore, as a treatment strategy for HE, alleviating ammonia toxicity is essential. In addition to restricting protein intake, synthetic disaccharides such as lactulose and lactitol, probiotics that improve gut flora, and rifaximin, an antibiotic with poor bioavailability, are also administrated. Additionally, branched‐chain amino acids and carnitine have also been administrated. Moreover, we investigated the current trend in the concomitant use of drugs with different mechanisms of action. In Japan, the V2 receptor antagonist tolvaptan can be administrated to hepatic cirrhosis patients with fluid retention. This drug is also useful as a countermeasure for hyponatremia in hepatic cirrhosis, and elucidating its effects in HE patients may therefore become an agenda in the future. These observations indicate that ammonia toxicity, gut flora control and low sodium control are major focuses in HE improvement and long‐term prognosis.</description><identifier>ISSN: 1386-6346</identifier><identifier>EISSN: 1872-034X</identifier><identifier>DOI: 10.1111/hepr.12495</identifier><identifier>PMID: 25604571</identifier><language>eng</language><publisher>Netherlands: Blackwell Publishing Ltd</publisher><subject>astrocyte ; brain edema ; cirrhosis ; hepatic encephalopathy ; hyperammonemia ; hyponatremia</subject><ispartof>Hepatology research, 2015-12, Vol.45 (12), p.1155-1162</ispartof><rights>2015 The Japan Society of Hepatology</rights><rights>2015 The Japan Society of Hepatology.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5275-a386a94bf251a7af66d6f73f2062a730cacf50e15a40e52b3fa3ebfa7553d2da3</citedby><cites>FETCH-LOGICAL-c5275-a386a94bf251a7af66d6f73f2062a730cacf50e15a40e52b3fa3ebfa7553d2da3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fhepr.12495$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fhepr.12495$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25604571$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Iwasa, Motoh</creatorcontrib><creatorcontrib>Takei, Yoshiyuki</creatorcontrib><title>Pathophysiology and management of hepatic encephalopathy 2014 update: Ammonia toxicity and hyponatremia</title><title>Hepatology research</title><addtitle>Hepatol Res</addtitle><description>Hyperammonemia is a major factor involved in the pathogenesis of hepatic encephalopathy (HE). Ammonia elicits astrocyte swelling and causes brain edema. In addition, hyponatremia, a condition frequently observed in hepatic cirrhosis, also exacerbates brain edema, potentially becoming a factor that exacerbates HE. Therefore, as a treatment strategy for HE, alleviating ammonia toxicity is essential. In addition to restricting protein intake, synthetic disaccharides such as lactulose and lactitol, probiotics that improve gut flora, and rifaximin, an antibiotic with poor bioavailability, are also administrated. Additionally, branched‐chain amino acids and carnitine have also been administrated. Moreover, we investigated the current trend in the concomitant use of drugs with different mechanisms of action. In Japan, the V2 receptor antagonist tolvaptan can be administrated to hepatic cirrhosis patients with fluid retention. This drug is also useful as a countermeasure for hyponatremia in hepatic cirrhosis, and elucidating its effects in HE patients may therefore become an agenda in the future. These observations indicate that ammonia toxicity, gut flora control and low sodium control are major focuses in HE improvement and long‐term prognosis.</description><subject>astrocyte</subject><subject>brain edema</subject><subject>cirrhosis</subject><subject>hepatic encephalopathy</subject><subject>hyperammonemia</subject><subject>hyponatremia</subject><issn>1386-6346</issn><issn>1872-034X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><recordid>eNp9kE1PwkAQhjdGI4he_AFmzybF_ejugjdCEEwIEoPReNkM7S5dpd2mLZH-e4sVj85lZpJnnkxehK4p6dOm7hKTF33KwqE4QV06UCwgPHw7bWY-kIHkoeygi7L8IIQqwsJz1GFCklAo2kWbJVSJz5O6dH7rNzWGLMYpZLAxqckq7C1u9FC5CJssMnkCW9-sSY0ZoSHe5TFU5h6P0tRnDnDl9y5yVatJ6txnUBUmdXCJzixsS3P123vo5WGyGs-C-dP0cTyaB5FgSgTQfAzDcG2ZoKDAShlLq7hlRDJQnEQQWUEMFRASI9iaW-BmbUEJwWMWA--h29YbFb4sC2N1XrgUilpTog9p6UNa-ietBr5p4Xy3Tk38hx7jaQDaAl9ua-p_VHo2WT4fpUF748rK7P9uoPjUUnEl9Otiqpd0uSJq8a7n_BtA3oZi</recordid><startdate>201512</startdate><enddate>201512</enddate><creator>Iwasa, Motoh</creator><creator>Takei, Yoshiyuki</creator><general>Blackwell Publishing Ltd</general><scope>BSCLL</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>201512</creationdate><title>Pathophysiology and management of hepatic encephalopathy 2014 update: Ammonia toxicity and hyponatremia</title><author>Iwasa, Motoh ; Takei, Yoshiyuki</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5275-a386a94bf251a7af66d6f73f2062a730cacf50e15a40e52b3fa3ebfa7553d2da3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>astrocyte</topic><topic>brain edema</topic><topic>cirrhosis</topic><topic>hepatic encephalopathy</topic><topic>hyperammonemia</topic><topic>hyponatremia</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Iwasa, Motoh</creatorcontrib><creatorcontrib>Takei, Yoshiyuki</creatorcontrib><collection>Istex</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Hepatology research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Iwasa, Motoh</au><au>Takei, Yoshiyuki</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pathophysiology and management of hepatic encephalopathy 2014 update: Ammonia toxicity and hyponatremia</atitle><jtitle>Hepatology research</jtitle><addtitle>Hepatol Res</addtitle><date>2015-12</date><risdate>2015</risdate><volume>45</volume><issue>12</issue><spage>1155</spage><epage>1162</epage><pages>1155-1162</pages><issn>1386-6346</issn><eissn>1872-034X</eissn><abstract>Hyperammonemia is a major factor involved in the pathogenesis of hepatic encephalopathy (HE). Ammonia elicits astrocyte swelling and causes brain edema. In addition, hyponatremia, a condition frequently observed in hepatic cirrhosis, also exacerbates brain edema, potentially becoming a factor that exacerbates HE. Therefore, as a treatment strategy for HE, alleviating ammonia toxicity is essential. In addition to restricting protein intake, synthetic disaccharides such as lactulose and lactitol, probiotics that improve gut flora, and rifaximin, an antibiotic with poor bioavailability, are also administrated. Additionally, branched‐chain amino acids and carnitine have also been administrated. Moreover, we investigated the current trend in the concomitant use of drugs with different mechanisms of action. In Japan, the V2 receptor antagonist tolvaptan can be administrated to hepatic cirrhosis patients with fluid retention. This drug is also useful as a countermeasure for hyponatremia in hepatic cirrhosis, and elucidating its effects in HE patients may therefore become an agenda in the future. These observations indicate that ammonia toxicity, gut flora control and low sodium control are major focuses in HE improvement and long‐term prognosis.</abstract><cop>Netherlands</cop><pub>Blackwell Publishing Ltd</pub><pmid>25604571</pmid><doi>10.1111/hepr.12495</doi><tpages>8</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1386-6346
ispartof Hepatology research, 2015-12, Vol.45 (12), p.1155-1162
issn 1386-6346
1872-034X
language eng
recordid cdi_crossref_primary_10_1111_hepr_12495
source Wiley Online Library - AutoHoldings Journals
subjects astrocyte
brain edema
cirrhosis
hepatic encephalopathy
hyperammonemia
hyponatremia
title Pathophysiology and management of hepatic encephalopathy 2014 update: Ammonia toxicity and hyponatremia
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T01%3A54%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-wiley_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pathophysiology%20and%20management%20of%20hepatic%20encephalopathy%202014%20update:%20Ammonia%20toxicity%20and%20hyponatremia&rft.jtitle=Hepatology%20research&rft.au=Iwasa,%20Motoh&rft.date=2015-12&rft.volume=45&rft.issue=12&rft.spage=1155&rft.epage=1162&rft.pages=1155-1162&rft.issn=1386-6346&rft.eissn=1872-034X&rft_id=info:doi/10.1111/hepr.12495&rft_dat=%3Cwiley_cross%3EHEPR12495%3C/wiley_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/25604571&rfr_iscdi=true